Alerts
Cholangiocarcinoma Just Made FGFR2 Testing Harder to Ignore
FDA has approved lirafugratinib for previously treated FGFR2 fusion- or rearrangement-positive advanced cholangiocarcinoma. Nearly half of patients responded. None of that matters if the alteration is never looked for.
Huntington’s Gene Therapy Moves Back Toward the FDA Door
Ebola in Congo’s Camps Shows the Human Cost of Lost Trust
AML’s Frontline Future Starts With Finding the Mutation Fast
Screwworm Turns Pet Treatment Into a One Health Preparedness Issue
Surviving Cancer Is Not the Same as Being Recovered
Alzheimer’s Agitation Moves Closer to a Phase 2 Readout
MenB Vaccination Moves From Baby Schedule to Student Outbreak Control
Sanofi’s Tzield moves type 1 diabetes into disease modification, but access may decide who benefits
AML’s Frontline Future Starts With Finding the Mutation Fast
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.